Viridian Therapeutics, Inc.
elegrobart (VRDN-003)
active TED
Resolved
7days ago
Phase 3 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 3 trial results for elegrobart (VRDN-003) in active TED are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“REVEAL-2 topline data in chronic TED on track for Q2 2026”